Spiro Medical Raises $67M to Pioneer a New Approach to Treating Severe Asthma

Spiro Medical has secured $67 million in Series A financing to advance what could become a fundamentally new way of treating severe asthma. Rather than focusing solely on inflammation or bronchodilation, the California-based medical device company is developing a Pulmonary Neuromodulation (PNM) system that targets the neural pathways involved in airway dysfunction.

The financing round was led by Andera Partners, Omega Funds, and Sherpa Healthcare Partners, with participation from global investors spanning Europe, the United States, and Asia. The capital will be used to complete development of a purpose-built neuromodulation system and to support the clinical and regulatory work required for approval in the United States.

At a time when millions of patients remain poorly controlled despite modern inhalers and biologics, Spiro Medical’s approach signals a growing interest in treating asthma as a neurologically mediated condition, rather than just being an inflammatory disease.

Why Severe Asthma Still Lacks Satisfactory Solutions ?

Asthma affects more than 28 million people in the United States and over 300 million globally, yet a significant subset of patients continues to experience frequent symptoms, exacerbations, and hospitalizations. For these patients, standard therapies often fall short.

While most treatments focus on calming inflammation or opening airways, researchers have long recognized that many asthma symptoms, wheezing, coughing, chest tightness, and shortness of breath, are partly regulated by the nervous system. Abnormal signaling in airway nerves can amplify reflexes that constrict airways and worsen breathing, even in the absence of acute inflammation.

Spiro Medical’s strategy is built on this insight: if neural reflex pathways can be precisely modulated, it may be possible to reduce symptoms at their source rather than constantly reacting to flare-ups.

Pulmonary Neuromodulation as a New Therapeutic Frontier

Neuromodulation has already reshaped care in areas such as chronic pain, epilepsy, Parkinson’s disease, and heart rhythm disorders. Spiro Medical aims to extend this paradigm into pulmonary medicine with a system specifically designed for the lungs.

The company’s Pulmonary Neuromodulation System is intended to interact directly with airway-related neural pathways, altering abnormal signaling patterns that contribute to asthma symptoms. Early human data and issued patents, referenced by the company’s leadership, suggest the approach has the potential to produce meaningful clinical impact.

Unlike drug-based therapies, neuromodulation systems can be adjusted, refined, and optimized over time, offering the possibility of a more personalized and durable treatment for patients with severe disease.

A Globally Backed Series A With Clinical Ambitions

The $67 million Series A reflects strong confidence from investors experienced in advanced medical technologies. Alongside lead investors Andera Partners, Omega Funds, and Sherpa Healthcare Partners, the round included HSG, Supernova Invest, Northern Light Venture Capital, and Hero Inc. Ltd, part of the India-based Hero Enterprise group.

According to Spiro Medical, the proceeds will fund the engineering of a purpose-built implantable neuromodulation system, as well as the clinical trials necessary to support regulatory submissions. The company is preparing for the rigorous testing required to demonstrate both safety and efficacy in a highly regulated therapeutic area.

Chairman of the board Raymond W. Cohen has described the opportunity as one with the potential to deliver meaningful impact for patients who have exhausted existing treatment options.

Leadership With Deep Neuromodulation Experience

Spiro Medical’s founding team brings experience across medicine, engineering, and neuromodulation development. The company was founded by Stephen Pyles, M.D., Kurt Gehlsen, M.D., Ph.D., Rinda Sama, and G. Jay Jiang, Ph.D., with leadership emphasizing prior work on implantable systems.

CEO Rinda Sama highlighted that the project begins with issued patents and early human data, a relatively rare starting point for a company at this stage. This foundation, combined with the team’s experience building neuromodulation devices, underpins confidence that Spiro Medical can translate scientific promise into a clinically viable system.

The appointment of new board members from Andera Partners, Omega Funds, and Sherpa Healthcare Partners further strengthens the company’s governance as it moves into its next phase.

Treating Asthma by Addressing the Nervous System

The scientific rationale behind pulmonary neuromodulation reflects a broader shift in how chronic diseases are understood. Increasingly, conditions once viewed as purely biochemical are being recognized as complex interactions between immune, structural, and neural systems.

By targeting airway nerves directly, Spiro Medical hopes to reduce hyperreactivity that drives symptoms, potentially offering relief to patients who do not respond well to inhaled therapies or biologics. If successful, this approach could expand beyond asthma to other respiratory conditions influenced by neural control.

A Long Regulatory Road, but a High-Impact Destination

Like all implantable medical devices, Spiro Medical’s system faces a long path through clinical trials, regulatory review, and post-market evaluation. Neuromodulation therapies demand especially high standards of evidence, given their direct interaction with neural pathways.

However, the size of the unmet need and the limitations of existing treatments definitely create a compelling case for innovation. For patients with severe asthma, even incremental improvements can dramatically affect quality of life, hospital utilization, and long-term outcomes.

What Spiro Medical Signals About the Future of Asthma Care ?

Spiro Medical’s Series A financing highlights growing interest in non-pharmaceutical approaches to chronic respiratory disease. As healthcare systems seek durable, cost-effective solutions for long-term conditions, device-based therapies that address root causes rather than symptoms are gaining attention.

If pulmonary neuromodulation proves effective, it could open an entirely new category within asthma care, one that complements existing therapies rather than replacing them outright.

Spiro Medical’s approach reflects a broader rethinking of chronic disease treatment, one that recognizes the nervous system as a critical lever in conditions long treated solely with drugs. While the clinical path ahead is complex, pulmonary neuromodulation could represent a meaningful shift for patients who have exhausted today’s asthma therapies.